The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Open accessPublished version of a preprint
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic 1,2. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms that determine such variable outcomes remain unresolved. Here we investigated CD4+ T cells that are reactive against the spike glycoprotein of SARS-CoV-2 in the peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors. We detected spike-reactive CD4+ T cells not only in 83% of patients with COVID-19 but also in 35% of healthy donors. Spike-reactive CD4+ T cells in healthy donors were primarily active against C-terminal epitopes in the spike protein, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared with N-terminal epitopes. Spike-protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to the C-terminal region of the spike proteins of the human endemic coronaviruses 229E and OC43, as well as that of SARS-CoV-2. This results indicate that spike-protein cross-reactive T cells are present, which were probably generated during previous encounters with endemic coronaviruses. The effect of pre-existing SARS-CoV-2 cross-reactive T cells on clinical outcomes remains to be determined in larger cohorts. However, the presence of spike-protein cross-reactive T cells in a considerable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming trials investigating COVID-19 vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This cross-reactivity largely originates from previous exposure to circulating common cold coronaviruses [110-116].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“lymphocytes from 20% to 50% of unexposed donors display significant reactivity to SARS-CoV-2 Ag peptide pools (Figure 6).”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [114]
In the citing paper
“the T cell responses against SARS-CoV-2 are highly multi-antigenic and multi-specific, with tens of different epitopes recognized by CD4+ and CD8+ T cells in a given individual.”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [52]
In the citing paper
“The dominant cytokine produced by SARS-CoV-2-specific CD4+ T cells from COVID-19 patients is IFNγ (Braun et al., 2020; Grifoni et al., 2020; Rydyznski Moderbacher et al., 2020; Weiskopf et al., 2020), with a clear IFNγ, tumor necrosis factor (TNF), IL-2 protein signature of canonical Th1 cells (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Peng et al., 2020; Sekine et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, the strikingly extended absence of SARS-CoV-2-specific CD4+ T cells was associated with severe or fatal COVID-19 (>day 22 PSO in some cases) (Braun et al., 2020; Rydyznski Moderbacher et al., 2020; Tan et al., 2020a).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“In contrast, substantial cross-reactive T cell memory has been reported, measurable in ∼28%–50% of people, depending on the study (Le Bert et al., 2020; Braun et al., 2020; Grifoni et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Braun et al., 2020
In the citing paper
“SARS-CoV-2 infection elicits a Th1 CD4+ T cell response, with IFNγ and IL-2 being the primary cytokines produced by these cells and some TNFα production as well112,126-129.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Specifically, when compared to those with mild COVID-19, patients with severe disease generated a weaker T cell response to the N-terminal portion of the SARS-CoV-2 S protein, a region that includes the critical receptor-binding domain (RBD)128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
In the citing paper
“Therefore, many individuals have existing memory T cells that were generated from endemic human coronavirus infections and can cross-react with SARS-CoV-2 epitopes, known as SARS-CoV-2 cross-reactive memory T cells128.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [128]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clustal W and Clustal X version 2.0
Larkin, M., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., López, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,598
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Needleman, S. B., & Wunsch, C. D. (1970) · Journal of Molecular Biology · doi:10.1016/0022-2836(70)90057-4 · Cited by 11,288
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
Corman, V. M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D. K. W., Bleicker, T., Brünink, S., Schneider, J. A., Schmidt, M. L., et al. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.3.2000045 · Cited by 7,266
Self-citationVirological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Self-citationWu, J. T., Leung, K., & Leung, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30260-9 · Cited by 4,389
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)
Diao, B., Wang, C., Tan, Y., Chen, X., Liu, Y., Ning, L., Chen, L., Li, M., Liu, Y., Wang, G., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00827 · Cited by 2,475
Cited by
Sorted by citations
Items 401–500 of 999
Shimizu, K., Iyoda, T., Sanpei, A., Nakazato, H., Okada, M., Ueda, S., Kato-Murayama, M., Murayama, K., Shirouzu, M., Harada, N., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02885-6 · Cited by 33
Meyer‐Arndt, L., Braun, J., Fauchère, F., Vanshylla, K., Loyal, L., Henze, L., Kruse, B., Dingeldey, M., Jürchott, K., Mangold, M., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329395 · Cited by 33
Self-citationSevere SARS‐CoV‐2 patients develop a higher specific T‐cell response
Demaret, J., Lefèvre, G., Vuotto, F., Trauet, J., Duhamel, A., Labreuche, J., Varlet, P., Dendooven, A., Stabler, S., Gachet, B., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1217 · Cited by 30
Lanini, S., Capone, S., Antinori, A., Milleri, S., Nicastri, E., Camerini, R., Agrati, C., Castilletti, C., Mori, F., Sacchi, A., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj1996 · Cited by 34
Petakh, P., Kamyshna, I. I., Nykyforuk, A., Yao, R., Imbery, J. F., Oksenych, V., Korda, M. M., & Kamyshnyi, O. (2022) · Viruses · doi:10.3390/v14030477 · Cited by 33
Zhang, B., Tian, J., Zhang, Q., Xie, Y., Wang, K., Qiu, S., Lu, K., & Liu, Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.761173 · Cited by 36
Qui, M., Bert, N. L., Chan, W. P. W., Tan, M. T. K., Hang, S. K., Hariharaputran, S., Sim, J. X. Y., Low, J. G. H., Ng, W., Wan, W. Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci159500 · Cited by 33
Benet, S., Blanch-Lombarte, O., Ainsua‐Enrich, E., Pedreño-López, N., Muñoz‐Basagoiti, J., Regué, D. R., Perez‐Zsolt, D., Peña, R., Jímenez, E., de la Concepción, M. L. R., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac406 · Cited by 33
COVID-19 in the Initiation and Progression of Atherosclerosis
Chidambaram, V., Kumar, A., Sadaf, M. I., Lu, E., Alaref, S. J., Tarun, T., Galiatsatos, P., Gulati, M., Blumenthal, R. S., Leucker, T. M., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.101107 · Cited by 33
Stankov, M. V., Cossmann, A., Bonifacius, A., Dopfer‐Jablonka, A., Ramos, G. M., Gödecke, N., Scharff, A. Z., Happle, C., Boeck, A.-L., Tran, A. T., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab555 · Cited by 31
Armann, J. P., Unrath, M., Kirsten, C., Lück, C., Dalpke, A. H., & Berner, R. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-049876 · Cited by 44
Meyer, M., Wang, Y., Edwards, D. K., Smith, G. R., Rubenstein, A. B., Ramanathan, P., Mire, C. E., Pietzsch, C. A., Chen, X., Ge, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci148036 · Cited by 43
Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs
Pan, K., Chiu, Y., Huang, E. L., Chen, M. M., Wang, J., Lai, I. P., Singh, S., Shaw, R., MacCoss, M. J., & Yee, C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111815118 · Cited by 32
Vogel, E., Kocher, K., Priller, A., Cheng, C., Steininger, P. A., Liao, B., Körber, N., Willmann, A., Irrgang, P., Held, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104294 · Cited by 31
Irsara, C., Egger, A., Prokop, W., Nairz, M., Loacker, L., Sahanic, S., Pizzini, A., Sonnweber, T., Mayer, W., Schennach, H., et al. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1758 · Cited by 29
An overview of the COVID‐19 complications in paediatric population: A pandemic dilemma
Seth, S., Rashid, F., & Khera, K. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14494 · Cited by 30
Nunes, M. C., Cutland, C., Klugman, K. P., & Madhi, S. A. (2021) · mBio · doi:10.1128/mbio.02347-20 · Cited by 32
Dysregulation of Pulmonary Responses in Severe COVID-19
Wu, D., & Yang, X. O. (2021) · Viruses · doi:10.3390/v13060957 · Cited by 29
Mellinghoff, S. C., Robrecht, S., Mayer, L., Weskamm, L. M., Dahlke, C., Gruell, H., Vanshylla, K., Schlößer, H., Thelen, M., Fink, A., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01500-1 · Cited by 30
Woldemeskel, B. A., Dykema, A. G., Garliss, C. C., Cherfils, S., Smith, K. N., & Blankson, J. N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156083 · Cited by 29
Immune-Guided Therapy of COVID-19
Ferraccioli, G., Gremese, E., Goletti, D., Petrone, L., Cantini, F., Ugel, S., Canè, S., & Bronte, V. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0675 · Cited by 30
Taus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 31
Therapeutic potential of autophagy in immunity and inflammation: current and future perspectives
Zuo, H., Chen, C., & Sa, Y. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00486-0 · Cited by 34
Human coronavirus OC43-elicited CD4+ T cells protect against SARS-CoV-2 in HLA transgenic mice
Alves, R. P. D. S., Timis, J., Miller, R., Valentine, K. M., Pinto, P. B. A., Gonzalez, A., Regla-Nava, J. Á., Maule, E., Nguyen, M. N., Shafee, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45043-2 · Cited by 29
SARS-CoV-2-reactive T cells in patients and healthy donors
Pia, L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0333-2 · Cited by 29
Kleen, T. O., Galdon, A. A., MacDonald, A. S., & Dalgleish, A. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02059 · Cited by 29
T cell phenotypes in COVID-19 - a living review
Hanna, S. J., Codd, A. S., Gea‐Mallorquí, E., Scourfield, D. O., Richter, F. C., Ladell, K., Borsa, M., Compeer, E. B., Moon, O. R., Galloway, S. A. E., et al. (2020) · Oxford Open Immunology · doi:10.1093/oxfimm/iqaa007 · Cited by 29
McGill, A. R., Khalil, R., Dutta, R., Green, R. J., Howell, M., Mohapatra, S., & Mohapatra, S. S. (2021) · Infectious Disease Reports · doi:10.3390/idr13010013 · Cited by 30
Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection
Ameratunga, R., Woon, S., Jordan, A., Longhurst, H. J., Leung, E. Y., Steele, R. H., Lehnert, K., Snell, R. G., & Brooks, A. E. S. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1905525 · Cited by 28
Thibeault, C., Mühlemann, B., Helbig, E. T., Mittermaier, M., Lingscheid, T., Tober‐Lau, P., Meyer‐Arndt, L., Meiners, L., Stubbemann, P., Haenel, S. S., et al. (2021) · Infection · doi:10.1007/s15010-021-01594-w · Cited by 29
Self-citationThe Many Faces of JAKs and STATs Within the COVID-19 Storm
Grant, A. H., Estrada, A. X., Ayala-Marin, Y. M., Alvidrez-Camacho, A. Y., Rodriguez, G., Robles‐Escajeda, E., Cadena-Medina, D. A., Rodriguez, A. C., & Kirken, R. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690477 · Cited by 29
Sealy, R. E., & Hurwitz, J. L. (2021) · Microorganisms · doi:10.3390/microorganisms9081643 · Cited by 30
Quiros‐Fernandez, I., Poorebrahim, M., Fakhr, E., & Arregui, A. C. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103610 · Cited by 32
Tormo, N., Navalpotro, D., Martínez-Serrano, M., Moreno, M., Grosson, F., Tur, I., Guna, M. R., Soriano, P., Tornero, A., & Gimeno, C. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115573 · Cited by 30
Innate and adaptive immune response in SARS-CoV-2 infection-Current perspectives
Zhu, Q., Xu, Y., Wang, T., & Xie, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1053437 · Cited by 32
Levite, M. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.357903 · Cited by 29
Jacobsen, E., Fabricius, D., Class, M., Topfstedt, F., Lorenzetti, R., Janowska, I., Schmidt, F., Staniek, J., Zernickel, M., Stamminger, T., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35055-1 · Cited by 29
Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology
Steiner, S., Schwarz, T., Corman, V. M., Sotzny, F., Bauer, S., Drosten, C., Volk, H., Scheibenbogen, C., & Hanitsch, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687449 · Cited by 29
Self-citationSARS‐CoV‐2 immunogenicity at the crossroads
Karamloo, F., & König, R. (2020) · Allergy · doi:10.1111/all.14360 · Cited by 28
The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research
Tan, A. S., Nerurkar, S. N., Tan, W. C. C., Goh, D. L. M., Lai, C. P. T., & Yeong, J. P.-S. (2020) · SLAS TECHNOLOGY · doi:10.1177/2472630320950248 · Cited by 28
Fouladseresht, H., Doroudchi, M., Rokhtabnak, N., Abdolrahimzadehfard, H., Roudgari, A., Sabetian, G., & Paydar, S. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.10.002 · Cited by 29
COVID-19: The Emerging Immunopathological Determinants for Recovery or Death
Ahmad, T., Chaudhuri, R., Joshi, M. C., Almatroudi, A., Rahmani, A. H., & Ali, S. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.588409 · Cited by 30
COVID-19 and Dentistry in 72 Questions: An Overview of the Literature
Derruau, S., Bouchet, J., Nassif, A., Baudet, A., Yasukawa, K., Lorimier, S., Prêcheur, I., Bloch‐Zupan, A., Pellat, B., Chardin, H., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040779 · Cited by 30
Antibody Response against SARS-CoV-2 and Seasonal Coronaviruses in Nonhospitalized COVID-19 Patients
Ruétalo, N., Businger, R., Althaus, K., Fink, S., Ruoff, F., Pogoda, M., Iftner, A., Ganzenmueller, T., Hamprecht, K., Flehmig, B., et al. (2021) · mSphere · doi:10.1128/msphere.01145-20 · Cited by 27
Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study
Барчук, А. А., Skougarevskiy, D., Титаев, К. Д., Shirokov, D., Raskina, Y. V., Novkunkskaya, A., Talantov, P., Isaev, A. A., Pomerantseva, E. A., Zhikrivetskaya, S. O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92206-y · Cited by 27
Effective chimeric antigen receptor T cells against SARS-CoV-2
Guo, X., Kazanova, A., Thurmond, S., Saragovi, H. U., & Rudd, C. E. (2021) · iScience · doi:10.1016/j.isci.2021.103295 · Cited by 29
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIVPreprint
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.15.431215 · Cited by 28
The scale and dynamics of COVID-19 epidemics across Europe
Dye, C., Cheng, R. C. H., Dagpunar, J. S., & Williams, B. G. (2020) · Royal Society Open Science · doi:10.1098/rsos.201726 · Cited by 30
Law, J. C., Koh, W. H., Budylowski, P., Lin, J., Yue, F., Abe, K. T., Rathod, B., Girard, M., Li, Z., Rini, J. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001067 · Cited by 27
Chauhan, N., Soni, S., Gupta, A., Aslam, M., & Jain, U. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26709 · Cited by 26
Simula, E. R., Manca, M. A., Jasemi, S., Uzzau, S., Rubino, S., Manchia, P., Bitti, A., Palermo, M., & Sechi, L. A. (2020) · Microorganisms · doi:10.3390/microorganisms8121993 · Cited by 28
Ng, K. T., Mohd-Ismail, N. K., & Tan, Y. (2021) · Vaccines · doi:10.3390/vaccines9020178 · Cited by 28
Poluektov, Y. O., George, M., Daftarian, P. M., & Delcommenne, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.008 · Cited by 27
Histomorphological patterns of regional lymph nodes in COVID-19 lungs
Haslbauer, J. D., Matter, M. S., Stalder, A. K., & Tzankov, A. (2021) · Der Pathologe · doi:10.1007/s00292-021-00945-6 · Cited by 28
Lehmann, A. A., Kirchenbaum, G. A., Zhang, T., Reche, P. A., & Lehmann, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.635942 · Cited by 27
Impaired Priming of SARS-CoV-2-Specific Naive CD8+ T Cells in Older Subjects
Gallerani, E., Proietto, D., Dallan, B., Campagnaro, M., Pacifico, S., Albanese, V., Marzola, E., Marconi, P., Caputo, A., Appay, V., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.693054 · Cited by 28
The “original antigenic sin” and its relevance for SARS-CoV-2 (COVID-19) vaccination
Rijkers, G. T., & van Overveld, F. J. (2021) · Clinical Immunology Communications · doi:10.1016/j.clicom.2021.10.001 · Cited by 27
van de Ven, K., van Dijken, H., Wijsman, L. A., Gomersbach, A., Schouten, T., Kool, J., Lenz, S., Roholl, P. J. M., Meijer, A., van Kasteren, P. B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.750229 · Cited by 26
Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing
Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 27
Hennings, V., Thörn, K., Albinsson, S., Lingblom, C., Andersson, K. M., Andersson, C., Järbur, K., Pullerits, R., Idorn, M., Paludan, S. R., et al. (2022) · European Journal of Immunology · doi:10.1002/eji.202149655 · Cited by 27
Bai, J., Chiba, A., Murayama, G., Kuga, T., Tamura, N., & Miyake, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.786586 · Cited by 27
Immunogenic epitope panel for accurate detection of non-cross-reactive T cell response to SARS-CoV-2
Titov, A., Shaikhutdinova, R., Shcherbakova, O. V., Serdyuk, Y. V., Sheetikov, S. A., Zornikova, K. V., Maleeva, A. V., Khmelevskaya, A. A., Dianov, D. V., Shakirova, N. T., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157699 · Cited by 26
Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors
Rovito, R., Augello, M., Ben-Haim, A., Bono, V., Monforte, A. D., & Marchetti, G. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912336 · Cited by 27
Lansdorp, P. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.943622 · Cited by 27
Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity
Beserra, D. R., Alberca, R. W., Branco, A. C. C. C., Oliveira, L. D. M., Andrade, M. M. D. S., Gozzi-Silva, S. C., Teixeira, F. M. E., Yendo, T. M., Duarte, A. J. D. S., & Sato, M. N. (2022) · Journal of Immunology Research · doi:10.1155/2022/9764002 · Cited by 30
Jia, L., Weng, S., Wu, J., Tian, X., Zhang, Y., Wang, X., Wang, J., Yan, D., Wang, W., Fang, F., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2117503 · Cited by 28
Kared, H., Redd, A. D., Bloch, E. M., Bonny, T. S., Sumatoh, H., Kairi, F., Carbajo, D., Abel, B., Newell, E. W., Bettinotti, M. P., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.08.330688 · Cited by 27
The starting line for COVID-19 vaccine development
Lee, N. L. S., & McGeer, A. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31239-3 · Cited by 25
Immune Correlates of COVID-19 Control
Poonia, B., & Kottilil, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569611 · Cited by 26
Kwarteng, A., Asiedu, E., Sakyi, S. A., & Asiedu, S. O. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110914 · Cited by 29
Structure-Based Modeling of SARS-CoV-2 Peptide/HLA-A02 Antigens
Nerli, S., & Sgourakis, N. G. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.553478 · Cited by 23
SARS-CoV-2 infection and COVID-19 severity in individuals with prior seasonal coronavirus infection
Gombar, S., Bergquist, T., Pejaver, V. R., Hammarlund, N. E., Murugesan, K., Mooney, S. D., Shah, N. H., Pinsky, B. A., & Banaei, N. (2021) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2021.115338 · Cited by 27
Demers‐Mathieu, V., DaPra, C., Mathijssen, G. B., & Medo, E. T. (2021) · Journal of Perinatology · doi:10.1038/s41372-021-01001-0 · Cited by 26
Immune profiling of COVID-19: preliminary findings and implications for the pandemic
Maecker, H. T. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002550 · Cited by 26
Vaccination reshapes the virus-specific T cell repertoire in unexposed adults
Pan, Y., Aiamkitsumrit, B., Bartolo, L., Wang, Y., Lavery, C. L. M., Marc, A., Holec, P. V., Rappazzo, C. G., Eilola, T., Gimotty, P. A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.023 · Cited by 29
Immune response to SARS‐CoV‐2 in children: A review of the current knowledge
Filippatos, F., Tatsi, E., & Michos, A. G. (2021) · Pediatric Investigation · doi:10.1002/ped4.12283 · Cited by 26
Ligotti, M. E., Pojero, F., Accardi, G., Aiello, A., Caruso, C., Duro, G., & Candore, G. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.725606 · Cited by 26
How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology
Waterlow, N. R., van Leeuwen, E., Davies, N. G., CMMID COVID-19 Working Group, Flasche, S., & Eggo, R. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2108395118 · Cited by 26
Lee, C., Gray, V., Teo, J. M. N., Tam, A. R., Fong, C. H.-Y., Lui, D. T. W., Pang, P., Chan, K. H., Hung, I. F., Tan, K. C. B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018393 · Cited by 26
Altosole, T., Rotta, G., Uras, C., Bornheimer, S. J., & Fenoglio, D. (2023) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113443 · Cited by 30
Takagi, A., & Matsui, M. (2020) · Journal of Virology · doi:10.1128/jvi.01837-20 · Cited by 25
Ferrantelli, F., Chiozzini, C., Manfredi, F., Giovannelli, A., Leone, P., & Federico, M. (2021) · Vaccines · doi:10.3390/vaccines9030240 · Cited by 24
McKeigue, P., McAllister, D., Caldwell, D., Gribben, C., Bishop, J., McGurnaghan, S. J., Armstrong, M., Delvaux, J., Colville, S., Hutchinson, S. J., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02021-5 · Cited by 25
Xu, K., An, Y., Li, Q., Huang, W., Han, Y., Zheng, T., Fang, F., Liu, H., Liu, C., Gao, P., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1959270 · Cited by 25
COVID-19 and gut immunomodulation
Roy, K., Agarwal, S., Banerjee, R., Paul, M. K., & Purbey, P. K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i46.7925 · Cited by 26
Pre-Pandemic Cross-Reactive Immunity against SARS-CoV-2 among Central and West African Populations
Souris, M., Tshilolo, L. M., Parzy, D., Ingoba, L. L., Ntoumi, F., Kamgaing, R. S., Ndour, M., Mbongi, D., Phoba, B., Tshilolo, M.-A., et al. (2022) · Viruses · doi:10.3390/v14102259 · Cited by 25
Current understanding of T cell immunity against SARS-CoV-2
Lu, X., & Yamasaki, S. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00242-6 · Cited by 23
Touizer, E., Alrubayyi, A., Ford, R., Hussain, N., Gerber, P. P., Shum, H.-L., Rees-Spear, C., Muir, L., Gea‐Mallorquí, E., Kopycinski, J. T., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105862 · Cited by 27
Rabaan, A. A., Al-Ahmed, S. H., Albayat, H., Alwarthan, S. M., Alhajri, M. M., Najim, M. A., Alshehail, B. M., Al-Adsani, W., Alghadeer, A., Abduljabbar, W. A., et al. (2023) · Medicina · doi:10.3390/medicina59030507 · Cited by 26
Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults
Samandari, T., Ongalo, J., McCarthy, K. D., Biegon, R., Madiega, P. A., Mithika, A., Orinda, J., Mboya, G., Mwaura, P., Anzala, O. A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170011 · Cited by 24
Yuen, R. R., Steiner, D., Pihl, R. M. F., Chavez, E. C., Olson, A., Smith-Mahoney, E. L., Baird, L. A., Korkmaz, F. T., Urick, P., Sagar, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.614676 · Cited by 22
Zaichuk, T. A., Nechipurenko, Y. D., Adzhubey, A. A., Оникиенко, С. Б., Черешнев, В. А., Zainutdinov, S. S., Kochneva, G. V., Sv, N., & Matveeva, O. V. (2020) · Molecular Biology · doi:10.1134/s0026893320060151 · Cited by 25
Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2
Furuse, Y., & Oshitani, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.583252 · Cited by 24
Does common cold coronavirus infection protect against severe SARS-CoV-2 disease?
Meyerholz, D. K., & Perlman, S. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144807 · Cited by 22
Pre-existing T Cell Memory against Zika Virus
Schouest, B., Grifoni, A., Pham, J. W., Mateus, J., Sydney, J., Brien, J. D., Silva, A. D. D., Balmaseda, Á., Harris, E., Sette, A., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00132-21 · Cited by 26
Pallikkuth, S., Williams, E., Pahwa, R., Hoffer, M. E., & Pahwa, S. G. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.092 · Cited by 25
COVID-19 Vaccines: Current Conditions and Future Prospects
Zieneldien, T., Kim, J., Cao, J. A., & Cao, C. (2021) · Biology · doi:10.3390/biology10100960 · Cited by 24
The association between first and second wave COVID-19 mortality in Italy
Vinceti, M., Filippini, T., Rothman, K. J., Federico, S. D., & Orsini, N. (2021) · BMC Public Health · doi:10.1186/s12889-021-12126-4 · Cited by 26
Immunoinformatics mapping of potential epitopes in SARS-CoV-2 structural proteins
Devi, Y. D., Goswami, H. B., Konwar, S., Doley, C., Dolley, A., Devi, A., Chongtham, C., Dowerah, D., Biswa, V., Jamir, L., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258645 · Cited by 25
SARS‐CoV‐2 memory B and T cell profiles in mild COVID‐19 convalescent patients
Gurevich, M., Zilkha‐Falb, R., Sonis, P., Magalashvili, D., Menascu, S., Flechter, S., Dolev, M., Mandel, M., & Achiron, A. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.12.309 · Cited by 24
Metadata
- Authors
- Braun, J., Loyal, L., Frentsch, M., Wendisch, D., Georg, P., Kurth, F., Hippenstiel, S., Dingeldey, M., Kruse, B., Fauchere, F., Baysal, E., Mangold, M., Henze, L., Lauster, R., Mall, M. A., Beyer, K., Röhmel, J., Voigt, S., Schmitz, J., Miltenyi, S., Demuth, I., Müller, M. A., Hocke, A., Witzenrath, M., Suttorp, N., Kern, F., Reimer, U., Wenschuh, H., Drosten, C., Corman, V. M., Giesecke-Thiel, C., Sander, L. E., & Thiel, A.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Technische Universität Berlin (DE)
- Robert Koch Institute (DE)
- Miltenyi Biotec (Germany) (DE)
- Brighton and Sussex Medical School (GB)
- JPT Peptide Technologies (Germany) (DE)
- Corresponding author
- Sander, Leif Erik
- Thiel, Andreas
- ORCID
- Braun, Julian
- Loyal, Lucie
- Frentsch, Marco
- Wendisch, Daniel
- Georg, Philipp
- Kurth, Florian
- Hippenstiel, Stefan
- Dingeldey, Manuela
- Fauchere, Florent
- Baysal, Emre
- Mangold, Maike
- Henze, Larissa
- Mall, Marcus A.
- Beyer, Kirsten
- Voigt, Sebastian
- Demuth, Ilja
- Müller, Marcel A.
- Hocke, Andreas
- Witzenrath, Martin
- Suttorp, Norbert
- Kern, Florian
- Reimer, Ulf
- Drosten, Christian
- Corman, Victor M.
- Giesecke-Thiel, Claudia
- Sander, Leif Erik
- Thiel, Andreas
- Venue
- Nature
- Published
- 2020-07-29
- Volume
- 587
- Issue
- 7833
- Pages
- 270-274
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3045971896
- Cited by
- 1,310
- References
- 41
- Citations by year
- 2026: 16 · 2025: 37 · 2024: 91 · 2023: 143 · 2022: 283 · 2021: 480 · 2020: 259
- FWCI
- 38.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Sussex Research Online (University of Sussex) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (KFO 339, SFB‐TR84)
- Bundesministerium für Bildung und Forschung
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, CD4+ T cells, spike protein, cross-reactive T cells, HCoV-229E, HCoV-OC43, C-terminal epitope, T cell immunity, COVID-19 vaccine design, healthy donors
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, Aged, 80 and over, Cell Line, Cross Reactions, Female, Humans, Lymphocyte Activation, Male, Middle Aged, Pneumonia, Viral, CD4-Positive T-Lymphocytes, Coronavirus Infections, Epitopes, T-Lymphocyte, Coronavirus 229E, Human, Coronavirus OC43, Human, Pandemics, Coronavirus NL63, Human, Healthy Volunteers, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
